Literature DB >> 9409440

Development of intimal thickening in superficial temporal arteries in patients with moyamoya disease.

M Aoyagi1, N Fukai, M Yamamoto, Y Matsushima, K Yamamoto.   

Abstract

To investigate the possible mechanism of neointimal formation in Moyamoya disease, we histologically examined the superficial temporal arteries and also investigated cultured smooth muscle cells (SMCs) from the arteries. Intimal thickening of the scalp arteries developed significantly at an early age in Moyamoya patients compared with control subjects. The histopathological findings of the neointima in scalp arteries were almost similar to those in intracranial arteries in Moyamoya patients. SMCs cultured from Moyamoya arteries responded significantly less to serum mitogens, especially to platelet derived growth factor (PDGF), than those of control patients, the finding of which was explained by the reduced number of PDGF receptor on Moyamoya SMCs. Our findings indicate the presence of systemic factors that promote migration and proliferation of SMCs from the media to the intima in Moyamoya disease. Our results suggest that alteration in vascular cells may contribute to the development of intimal thickening in Moyamoya disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409440     DOI: 10.1016/s0303-8467(97)00046-2

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  Histopathological features of middle cerebral artery and superficial temporal artery from patients with moyamoya disease and enlightenments on clinical treatment.

Authors:  Shou-Jia Sun; Jian-Jian Zhang; Zheng-Wei Li; Zhong-Wei Xiong; Xiao-Lin Wu; Sheng Wang; Kai Shu; Jin-Cao Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

2.  Caveolin-1 Promoted Collateral Vessel Formation in Patients With Moyamoya Disease.

Authors:  Jinbing Zhao; Zhiqiang Yu; Yanping Zhang; Cheng Qiu; Guangxu Zhang; Lijiu Chen; Shengxue He; Jun Ma
Journal:  Front Neurol       Date:  2022-04-26       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.